Local Ancestry‐Informed Candidate Pathway Analysis of Warfarin Stable Dose in Latino Populations

So excited to see this publication finally come out. This was my first project I worked on with the Karnes Lab and I really think it became a diamond from the rough.

Local Ancestry‐Informed Candidate Pathway Analysis of Warfarin Stable Dose in Latino Populations

Accuracy of warfarin dose prediction algorithms may be improved by including data from diverse populations in genetic studies of dose variability. Here, we surveyed single nucleotide polymorphisms in vitamin K-related genetic pathways for association …

Machine Learning for Prediction of Stable Warfarin Dose in US Latinos and Latin Americans

Populations used to create warfarin dose prediction algorithms largely lacked participants reporting Hispanic or Latino ethnicity. While previous research suggests nonlinear modeling improves warfarin dose prediction, this research has mainly focused …

Multi‐site Investigation of Genetic Determinants of Warfarin Dose Variability in Latinos

We conducted a multi‐site investigation of genetic determinants of warfarin dose variability in Latinos from the U.S. and Brazil. Patients from four institutions in the United States (n = 411) and Brazil (n = 663) were genotyped for VKORC1 c.‐1639G …

ASCPT Presidential Trainee 2021

I’ve been MIA! Grad school is exhausting! Alas, it’s summer 2021 and I’m back to update my site with some w’s! American Society of Clinical Pharmacology and Therapeutics Annual Meeting I presented my work on warfarin stable dose prediction in a diverse population featuring a large proportion of Hispanic/Latino reporting warfarin users at the ASCPT 2021 Annual Meeting (,virtually).

PGRN Annual Meeting 2020

Pharmacogenomics Global Research Network (Actually this name is brand new, like yesterday. So in October, when this meeting occurred, the PGRN was still the PharmacoGenomics Research Network). I presented a poster at the PGRN Annual Meeting in October 2020.

Warfarin Pharmacomicrobiomics

Warfarin pharmacogenomics has been on my mind for quite awhile. Warfarin acts as an anticoagulant by inhibiting the vitamin K cycle which is responsible for creating blood clotting factors. When I learned that vitamin K was produced by bacteria in the gut microbiome, I hypothesized that vitamin K producing capability of the gut microbiome would be associated with warfarin dose requirements.